Patent · US Active

Anti-TIGIT antibodies

US10329349B2 · kind B2 · utility

5Cited by

10References

26Claims

0Family size

Assignee

iTeos Therapeutics SA · BE

Inventors

Anthony B. Cooper · South San Francisco, US
Christophe Queva · Bainbridge Island, US
Sofie Denies · Gosselies, BE
Catherine Hoofd · Gosselies, BE
Julia Cuende · Gosselies, BE
Gregory Driessens · Ottignies, BE
Florence Lambolez · Gosselies, BE

Key dates

Filing date	Oct 12, 2018
Grant date	Jun 25, 2019
Priority date	—
Expiry date	Oct 12, 2038

Classification

Technology area (CPC Y)Emerging Cross-Sectional Technologies
CPC primaryY02A50/30
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Anti-TIGIT antibodies and antigen binding fragments thereof that inhibit TIGIT-mediated signalling are provided, together with combinations comprising said antibodies or antigen binding fragments thereof and methods for their use.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.